Craniopharyngioma, Child clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, not yet accepting patients
The current study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young adults with craniopharyngioma.
San Francisco, California
Our lead scientists for Craniopharyngioma, Child research studies include Sabine Mueller, MD, PhD, MAS.